HuGE Literature Finder
Records
1
-
30
| Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, transfusion and cell therapy 2019 Oct . Porto-Soares Moysés Antonio, de Oliveira Rafael Daltro, Cortopassi Gabriel Macedo, Machado-Neto João Agostinho, Palma Leonardo Carvalho, Figueiredo-Pontes Lorena Lobo |
| [Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases]. Zhongguo shi yan xue ye xue za zhi 2018 Aug 26 (4): 1122-1128. Li Zhen-Ling, Gao Li, Zhang Hui, Zhang Chun-Xia, Chen Yan-Rong, Huang Fan-Zhou, Gong Ming, Gao Ya-Yue, Tang Yin, Ma Yi-G |
| GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms. Annals of laboratory medicine 2018 Jul 38 (4): 296-305. Yang Naery, Park Sholhui, Cho Min Sun, Lee Miae, Hong Ki Sook, Mun Yeung Chul, Seong Chu Myong, Huh Hee Jin, Huh Jungw |
| CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2017 Oct 1-4. Ojeda Mara Jorgelina, Bragós Irma Margarita, Calvo Karina Lucrecia, Williams Gladis Marcela, Carbonell María Magdalena, Pratti Arianna Flav |
| Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients. Hematology (Amsterdam, Netherlands) 2017 Apr 1-8. Limsuwanachot N, Rerkamnuaychoke B, Chuncharunee S, Pauwilai T, Singdong R, Rujirachaivej P, Chareonsirisuthigul T, Siriboonpiputtana |
| Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations. Annals of hematology 2016 Dec . Lekovic Danijela, Gotic Mirjana, Skoda Radek, Beleslin-Cokic Bojana, Milic Natasa, Mitrovic-Ajtic Olivera, Nienhold Ronny, Sefer Dijana, Suboticki Tijana, Buac Marijana, Markovic Dragana, Diklic Milos, Cokic Vladan |
| Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms. Hematology (Amsterdam, Netherlands) 2016 Oct 21 (9): 520-5. Trifa Adrian P, Banescu Claudia, Dima Delia, Bojan Anca S, Tevet Mihaela, Moldovan Valeriu G, Vesa ?tefan C, Murat Meilin, Pop Ioan V, Skrypnyk Cristina, Popp Radu |
| Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing. American journal of clinical pathology 2016 Oct 146 (4): 448-55. Gardner Juli-Anne, Peterson Jason D, Turner Scott A, Soares Barbara L, Lancor Courtney R, Dos Santos Luciana L, Kaur Prabhjot, Ornstein Deborah L, Tsongalis Gregory J, de Abreu Francine |
| Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 2016 Jul . Min-Gu Kang, Hyun-Woo Choi, Jun Hyung Lee, Yong Jun Choi, Hyun-Jung Choi, Jong-Hee Shin, Soon-Pal Suh, Szardenings Michael, Hye-Ran Kim, Myung-Geun Sh |
| The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms. Blood cells, molecules & diseases 2016 Jul 59 25-30. Berzoti-Coelho Maria Gabriela, Ferreira Aline Fernanda, de Souza Nunes Natalia, Pinto Mariana Tomazini, Júnior Maurício Cristiano Rocha, Simões Belinda Pinto, Martínez-A Carlos, Souto Elizabeth Xisto, Panepucci Rodrigo Alexandre, Covas Dimas Tadeu, Kashima Simone, Castro Fabíola Att |
| Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2016 Jun 32 (Suppl 1): 112-6. Rashid Munazza, Ahmed Rifat Zubair, Ahmed Shariq, Nadeem Muhammad, Ahmed Nuzhat, Shamsi Tahir Sult |
| Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients. Blood cells, molecules & diseases 2016 Mar 57 54-7. Macedo Luciana Conci, de Cesare Quintero Fernanda, Pagliari-E-Silva Sara, Pagnano Katia Borgia Barbosa, Rodrigues Camila, de Alencar Josiane Bazzo, Sell Ana Maria, Visentainer Jeane Eliete Lagui |
| Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? Asian Pacific journal of cancer prevention : APJCP 2016 17 (3): 923-6. Ahmed Rifat Zubair, Rashid Munazza, Ahmed Nuzhat, Nadeem Muhammad, Shamsi Tahir Sult |
| The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. PloS one 2016 11 (4): e0154183. Chen Yan, Fang Fang, Hu Yang, Liu Qian, Bu Dingfang, Tan Mei, Wu Liusong, Zhu Pi |
| Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015 Oct . Krahling Tunde, Balassa Katalin, Kiss Katalin P, Bors Andras, Batai Arpad, Halm Gabriella, Egyed Miklos, Fekete Sandor, Remenyi Peter, Masszi Tamas, Tordai Attila, Andrikovics Hajnal |
| JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. International journal of laboratory hematology 2015 Oct 37 (5): 654-60. Macedo L C, Santos B C, Pagliarini-E-Silva S, Pagnano K B B, Rodrigues C, Quintero F C, Ferreira M E, Baraldi E C, Ambrosio-Albuquerque E P, Sell A M, Visentainer J E |
| The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. American journal of clinical pathology 2015 Jul 144 (1): 165-71. Lin Yani, Liu Enbin, Sun Qi, Ma Jiao, Li QingHua, Cao Zeng, Wang Jun, Jia Yujiao, Zhang Hongju, Song Zhen, Ai Xiaofei, Shi Lihui, Feng Xiaofang, Li Chenwei, Wang Jianxiang, Ru K |
| Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. PloS one 2013 8 (1): 1. Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, Ryang DW, Shin MG |
| TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. BioMed research international 2013 2013 929840. Patriarca Andrea, Colaizzo Donatella, Tiscia Gianluca, Spadano Raffaele, Di Zacomo Silvia, Spadano Antonio, Villanova Ida, Margaglione Maurizio, Grandone Elvira, Dragani Alfre |
| [Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2012 Dec 33 (12): 12. Zhang XY, Maimaitili Y, Li Y, An L, Mao M, Fu L, Baier M, Wang XM |
| Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica 2012 Oct 97 (10): 1582-5. Schnittger Susanne, Bacher Ulrike, Eder Christiane, Dicker Frank, Alpermann Tamara, Grossmann Vera, Kohlmann Alexander, Kern Wolfgang, Haferlach Claudia, Haferlach Torst |
| JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil. Genetic testing and molecular biomarkers 2012 Feb . Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, Albuquerque DM, Santos MN, Fertrin KY, Costa FF, Araújo AD, Bezerra MA |
| Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis. Journal of the Formosan Medical Association = Taiwan yi zhi 2012 Jan 111 (1): 34-40. Ho Ching-Liang, Wu Yi-Ying, Hung Hsiu-Man, Chang Ping-Ying, Kao Wei-You, Chen Yeu-Chin, Chao Tsu- |
| [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics]. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 2011 Aug 19 (4): 916-20. Zhu Jun-Fang, Liu Yuan, Liu Pei, Jia Ming-Feng, Cheng Juan, Zhao |
| JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathologie-biologie 2011 Aug 59 (4): e89-92. Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi |
| [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms]. The Korean journal of laboratory medicine 2010 Dec 30 (6): 567-74. Kim Jeong Tae, Cho Yong Gon, Choi Sam Im, Lee Young Jin, Kim Hye Ran, Jang Sook Jin, Moon Dae Soo, Park Young Jin, Park Ge |
| Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. British journal of haematology 2009 Jul 146 (2): 150-7. Medinger Michael, Skoda Radek, Gratwohl Alois, Theocharides Alexandre, Buser Andreas, Heim Dominik, Dirnhofer Stephan, Tichelli André, Tzankov Alexand |
| [Tyrosine kinase JAK2V617F mutation in human myeloproliferative disorders]. Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology 2009 Jun 17 (3): 541-4. Xu Yuan-Yuan, Li Hui-Min, Li Xiao-Jin, Yang Ling, Hu Deng-Mi |
| TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 May 23 (5): 905-11. Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho T L, Patel J, Gangat N, Finke C M, Schwager S, Mullally A, Li C-Y, Hanson C A, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland D G, Levine R |
| Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm. Annals of clinical and laboratory science 2009 39 (4): 345-50. Malysz Jozef, Crisan Domni |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: